// App-Quantinova.ai

P495 : Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

Researchers

Presenter

  • Peyrin-Biroulet, L

Principal Investigators

  • Panaccione, R

  • Gasink, C

  • Hoops, T

  • Izanec, J.L

  • Ma, T

  • Nazar, M

  • Bravata, I

  • Lahaye, M

  • Irving, P.M

  • Loftus, E.V

  • Danese, S

  • Sands, B.E

Medical Centers

  • University hospital, Gastro-enterology, Vandoeuvre-les-Nancy, France

  • University of Calgary, Division of Gastroenterology & Hepatology, Calgary Alberta, Canada

  • Janssen, Immunology, Horsham, United States

  • Janssen, Biostatistics, Horsham, United States

  • Janssen, Immunology, Warsaw, Poland

  • Janssen, Immunology, Milan, Italy

  • Janssen-Cilag BV, Biostatistics, Breda, Netherlands

  • Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

  • Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Minnesota, United Kingdom

  • Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy

  • Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States

Locations

  • France

  • Canada

  • United States

  • Poland

  • Italy

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved